TRVN - Trevena, Inc.
1.4500 -0.04 (-2.68%)
After hours: 7:38PM EDT
| Previous Close | 1.5000 |
| Open | 1.4900 |
| Bid | 1.4800 x 2200 |
| Ask | 1.5200 x 4000 |
| Day's Range | 1.4401 - 1.5000 |
| 52 Week Range | 0.3820 - 3.5780 |
| Volume | 403,563 |
| Avg. Volume | 3,783,474 |
| Market Cap | 137.607M |
| Beta (3Y Monthly) | 5.66 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4180 |
| Earnings Date | May 1, 2019 - May 6, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 2.63 |
- Zacks•7 days ago
Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study
Mallinckrodt (MNK) ends enrollment in the phase III study on StrataGraft, a regenerative skin tissue used in patients with thermal burns.
- Simply Wall St.•11 days ago
Introducing Trevena (NASDAQ:TRVN), The Stock That Tanked 83%
Trevena, Inc. (NASDAQ:TRVN) shareholders will doubtless be very grateful to see the share price up 164% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. Indeed, the share...
- GlobeNewswire•11 days ago
AMAG Pharmaceuticals Appoints New Members to Board of Directors
“We are pleased to welcome Dr. Phillips and Ms. O’Brien to AMAG’s board,” said Gino Santini, chairman of the board of AMAG. “As AMAG continues to invest and focus on the development and commercialization of novel pharmaceutical products that address unmet medical needs, the deep experience and expertise that Dr. Phillips and Ms. O’Brien each bring will be invaluable to AMAG.
- Zacks•last month
Trevena (TRVN) Gains As Market Dips: What You Should Know
Trevena (TRVN) closed at $1.70 in the latest trading session, marking a +1.19% move from the prior day.
- Thomson Reuters StreetEvents•last month
Edited Transcript of TRVN earnings conference call or presentation 13-Mar-19 12:00pm GMT
Q4 2018 Trevena Inc Earnings Call
- Zacks•last month
Will Trevena Continue to Surge Higher?
As of late, it has definitely been a great time to be an investor in Trevena.
- Zacks•last month
Puma Biotech's (PBYI) Nerlynx Gets Approval in Australia
Puma Biotech (PBYI) gains an approval in Australia for Nerlynx as an extended adjuvant treatment in adult patients with early stage HER2-positive breast cancer.
- ACCESSWIRE•last month
Watch These Four Healthcare Stocks Set The Pace On Tuesday
Recently, we've seen healthcare companies demonstrate their collective abilities to meet the growing challenges presented by infectious diseases and ailments, with innovative treatment options and medical technologies. Premier Health Group (PHGRF) (PHGI), Vaxart Inc (VXRT), BioPharmX Corporation (NYSE American: BPMX), and Trevena Inc (TRVN) are 4 healthcare companies worth looking into on Tuesday. Premier Health will be partnering with BCT to enable patients and care providers improved monitoring of chronic disease progression and management of chronic conditions, such as diabetes, using BCT's proprietary AI technology.
- Zacks•last month
Is Trevena (TRVN) Stock Outpacing Its Medical Peers This Year?
Is (TRVN) Outperforming Other Medical Stocks This Year?
- American City Business Journals•last month
Trevena says it has 'clear path' to resubmit application for experimental pain medicine
The company could not say exactly when it will resubmit is new drug application for oliceridine, which was rejected by the FDA late last year.
- Zacks•last month
PDL BioPharma (PDLI) Q4 Earnings Top Mark, Revenues Fall Y/Y
PDL BioPharma's (PDLI) earnings exceed estimates in Q4. Lower royalties as well as weak product sales induce a downfall in year-over-year revenues.
- Zacks•last month
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.
- Zacks•last month
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
- Associated Press•last month
Trevena: 4Q Earnings Snapshot
On a per-share basis, the Chesterbrook, Pennsylvania-based company said it had a loss of 10 cents. The biopharmaceutical company posted revenue of $232,000 in the period. For the year, the company reported ...
- GlobeNewswire•last month
Trevena Reports Fourth Quarter and Full Year 2018 Results
— Company announces submission of oliceridine healthy volunteer study protocol and analysis plan to FDA — — Successful fundraising extends cash runway into 3Q 2020 —Company to.
- GlobeNewswire•last month
Trevena Announces Publication of APOLLO-1 Results in The Journal of Pain Research Highlighting Oliceridine’s Potential for Management of Moderate-to-Severe Acute Pain
The publication, “APOLLO-1: A randomized placebo- and active-controlled phase III study investigating oliceridine (TRV130), a G protein–biased ligand at the µ-opioid receptor, for management of moderate-to-severe acute pain following bunionectomy,” with lead author, Eugene R Viscusi, M.D.,Professor of Anesthesiology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, is available online at https://www.dovepress.com/journal-of-pain-research-archive41. “In this study, oliceridine was found to provide relief that was statistically superior to placebo in patients with moderate-to-severe acute post-surgical pain,” said Dr. Viscusi.
- ACCESSWIRE•2 months ago
These Four Tech Stocks Could Test March Highs
As we've seen over the last few years, tech companies have invested resources in artificial intelligence, automation, quantum computing, and augmented reality to pioneer technologies to drive society into the future. ParcelPal Technology Inc (PTNYF) (PKG), Trevena Inc (TRVN), China Finance Online Co. Limited (JRJC), and Luna Innovations Incorporated (LUNA) represent 4 tech stocks on the rise on Monday. The Company is focused on improving the lives of their customers through their on-demand marketplace where customers can purchase what they need and have their goods delivered within an hour.
- GlobeNewswire•2 months ago
Trevena to Report Fourth Quarter and Full Year 2018 Results on March 13, 2019
CHESTERBROOK, Pa., March 04, 2019 -- Trevena, Inc. (NASDAQ: TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
- Simply Wall St.•2 months ago
How Much Of Trevena, Inc. (NASDAQ:TRVN) Do Institutions Own?
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you want to know who reallyRead More...
- ACCESSWIRE•2 months ago
Biotech Stocks Set to Pop
HENDERSON, NV / ACCESSWIRE / February 7, 2019 / Biotech stocks are what growth investors thrive on. The rewards can be staggering - prices on biotechnology shares can literally double overnight - but the ...
- ACCESSWIRE•2 months ago
Top Cannabis and Biotech Stocks To Watch
HENDERSON, NV / ACCESSWIRE / February 6, 2019 / Cannabis and Biotech are in the middle of a massive comebacks, several small-cap plays in the sectors are prime for investors, here's a few to start researching. ...
- GlobeNewswire•2 months ago
Trevena to Present at the 21st Annual BIO CEO & Investor Conference
CHESTERBROOK, Pa., Feb. 05, 2019 -- Trevena, Inc. (NASDAQ:TRVN), a biopharmaceutical company focused on the development and commercialization of new and innovative treatment.
- GlobeNewswire•3 months ago
Market Trends Toward New Normal in CoreLogic, Nasdaq, Nevro, Blue Apron, Unisys, and Trevena — Emerging Consolidated Expectations, Analyst Ratings
NEW YORK, Feb. 01, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- American City Business Journals•3 months ago
Trevena to sell stock, makes progress on resubmitting new drug application
The Chester County biopharmaceutical expects to initiate a new study for its experimental pain medicine, requested by the FDA, during the first half of this year.
